<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931668</url>
  </required_header>
  <id_info>
    <org_study_id>SMHC-180</org_study_id>
    <secondary_id>TPN672-KYHY-201801</secondary_id>
    <nct_id>NCT03931668</nct_id>
  </id_info>
  <brief_title>Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers</brief_title>
  <official_title>A Single Site, Randomized, Double-blind, Placebo-controlled, Incremental Phase I Clinical Trial: to Evaluate the Tolerance, PK and PD Effects of TPN-672 Maleate in Chinese Healthy Volunteers After Single Dose Administration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Kanion Pharmaceutical Co.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-site, randomized, double-blind, placebo-controlled, incremental phase I
      clinical trial to evaluate preliminarily the tolerance, pharmacokinetics and pharmacodynamic
      effects of TPN672 maleate in Chinese healthy volunteers after single dose administration.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2019</start_date>
  <completion_date type="Anticipated">December 17, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of Subjects with adverse events during clinical trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Maximum Plasma Concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>48 hours</time_frame>
    <description>Area Under the Curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax</measure>
    <time_frame>48 hours</time_frame>
    <description>Time to Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2</measure>
    <time_frame>48 hours</time_frame>
    <description>Time of half life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR</measure>
    <time_frame>48 hours</time_frame>
    <description>Apparent Clearance Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ADV</measure>
    <time_frame>48 hours</time_frame>
    <description>Apparent Distribution Volume</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prolactin</measure>
    <time_frame>48 hours</time_frame>
    <description>serum prolactin test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>temperature</measure>
    <time_frame>48 hours</time_frame>
    <description>ear temperature</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse rate</measure>
    <time_frame>48 hours</time_frame>
    <description>pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory</measure>
    <time_frame>48 hours</time_frame>
    <description>frequency of respiratory per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>48 hours</time_frame>
    <description>lying blood pressureï¼Œ systolic and diastolic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram(ECG)</measure>
    <time_frame>48 hours</time_frame>
    <description>the number of subjects with abnormal ECG report by 12-lead electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc</measure>
    <time_frame>48 hours</time_frame>
    <description>QTc interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extrapyramidal symptoms</measure>
    <time_frame>48 hours</time_frame>
    <description>Simpson Angus Rating Scale (SAS), total score ranges from 0 to 40, of which lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Involuntary Movement</measure>
    <time_frame>48 hours</time_frame>
    <description>Abnormal Involuntary Movement Scale (AIMS), total score ranges from 0 to 14, of which lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Akathisia</measure>
    <time_frame>48 hours</time_frame>
    <description>Barnes Akathisia Rating Scale (BARS), total score ranges from 0 to 40, of which lower values represent a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Interleukin-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-4</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Interleukin-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-1</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Interleukin-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-2</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Interleukin-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INF-gamma</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Interferon-gamma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-alpha</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Tumor necrosis factor-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-HT</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of serotonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DA</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Dopamine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NE</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Norepinephrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BDNF</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Brain-derived neurotrophic factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamic acid</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of Glutamic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GABA</measure>
    <time_frame>48 hours</time_frame>
    <description>Serum concentration of gamma-aminobutyric acid</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>PHA1A</condition>
  <arm_group>
    <arm_group_label>0.125mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of TPN-672 0.125mg, 2 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 0.25mg, 10 subjects (8 for TPN-672, 2 for placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 0.5mg, 10 subjects (8 for TPN-672, 2 for placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 1mg, 10 subjects (8 for TPN-672, 2 for placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 2mg, 10 subjects (8 for TPN-672, 2 for placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 3mg, 10 subjects (8 for TPN-672, 2 for placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of 4mg, 10 subjects (8 for TPN-672, 2 for placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN-672</intervention_name>
    <description>single dose of TPN-672 maleate tablet</description>
    <arm_group_label>0.125mg single dose</arm_group_label>
    <arm_group_label>0.25mg single dose</arm_group_label>
    <arm_group_label>0.5mg single dose</arm_group_label>
    <arm_group_label>1mg single dose</arm_group_label>
    <arm_group_label>2mg single dose</arm_group_label>
    <arm_group_label>3mg single dose</arm_group_label>
    <arm_group_label>4mg single dose</arm_group_label>
    <other_name>TPN-672 maleate tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight &gt; 50kg(male) or &gt; 45kg(female), 19 &lt;BMI&lt;26 kg/m2.

          -  Good communication with investigators, willingness and ability to abide by the
             lifestyle restrictions stipulated in clinical trial

          -  Women or men within childbearing age do not have a fertility plan within 3 months
             after the end of the trial, and agree to adopt contraceptive measures approved (such
             as intrauterine device, condom, sperm killing gel, condom, uterine cap, etc.)
             throughout the clinical trial period.

          -  Fully understand the purpose and requirements of the trial, voluntarily participate in
             the clinical trial and sign the written informed consent, can complete the entire
             trial process according to the requirements of the trial.

        Exclusion Criteria:

          -  Investigator determined that there were diseases or functional disorders affecting
             clinical trials, including, but not limited to, central nervous system, cardiovascular
             system, respiratory system, digestive system, urinary system, endocrine system and
             blood system.

          -  Mental illness or previous history of mental illness;

          -  Have a history of ophthalmic diseases, such as abnormal color vision, retinitis
             pigmentosa, macular degeneration, etc.

          -  Have a history of malignant tumors or other diseases that are not suitable for
             clinical trials;

          -  Any surgical condition or condition that may significantly affect drug absorption,
             distribution, metabolism and excretion, or that may pose a hazard to the subjects
             participating in the study, such as history of gastrointestinal surgery (gastrectomy,
             gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction
             or dysuria, gastroenteritis, gastrointestinal ulcer, gastrointestinal bleeding, etc.

          -  Those who are known to have a history of drug allergy, allergic disease or allergic
             constitution of the tested drug ingredients or similar drugs;

          -  Smokers who smoked more than 10 cigarettes or the same amount of tobacco per day in
             the first year of screening;

          -  Alcohol addiction within 1 year before screening, with an average weekly alcohol
             intake of more than 14 units (1 unit = 285 ml beer or 25 ml spirits or 150 ml wine) or
             positive alcohol breath test;

          -  Those who had a history of drug abuse or drug abuse within 1 year before screening, or
             those who had positive urinary drug screening;

          -  Physical examination, current medical history and vital signs were found to be
             abnormal by researchers and have clinical significance.

          -  Resting pulse rate &lt; 55/min or &gt; 100/min; systolic pressure &lt; 90 mmHg or &gt; 140 mmHg,
             diastolic pressure &lt; 60 mmHg or &gt; 90 mmHg;

          -  12-lead electrocardiogram (ECG) examination was found to be abnormal by investigator
             and had clinical significance; or the following ECG abnormalities occurred: PR
             interval &gt; 220 ms, QRS complex wave duration &gt; 120 ms, long QT syndrome (QTc &gt; 450
             ms);

          -  Family history of sudden cardiac death (less than 40 years old);

          -  Abnormal blood routine examination and urine routine examination have clinical
             significance.

          -  Aspartate transferase (AST), alanine transferase (ALT), creatinine (Cr), urea nitrogen
             (BUN) exceeded the normal upper limit.

          -  HBsAg, HCV-Ab, HIV-Ab and TRUST positive patients;

          -  Pregnant or lactating women or male subjects whose spouses have child-rearing plans
             within three months;

          -  Those who took any medicine within 2 weeks before admission, including prescription
             and non-prescription drugs;

          -  Blood donation or blood loss (&gt; 200 ml) within 3 months before admission, or a history
             of using blood products;

          -  Participated in any clinical trials within 3 months before admission;

          -  Those who had a history of operation within 3 months before admission, or who had not
             recovered from the operation, or who had anticipated operation plan during the trial
             period;

          -  Do not agree to abide by the following conditions during the experiment: prohibit the
             use of tobacco, alcohol or caffeine-containing beverages, avoid strenuous exercise;

          -  Personnel directly related to this clinical trial;

          -  Investigator believes that other subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifeng SHEN, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yifeng SHEN, MD PhD</last_name>
    <phone>86-21-34773657</phone>
    <email>shenyifeng@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huafang LI, MD PhD</last_name>
      <phone>86-21-34773107</phone>
      <email>lhlh_5@163.com</email>
    </contact>
    <investigator>
      <last_name>Huafang LI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tolerance</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>TPN-672</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

